vs
BALCHEM CORP（BCPC）与Essex Property Trust（ESS）财务数据对比。点击上方公司名可切换其他公司
Essex Property Trust的季度营收约是BALCHEM CORP的1.8倍（$479.6M vs $263.6M），Essex Property Trust净利率更高（17.9% vs 14.9%，领先3.0%），BALCHEM CORP同比增速更快（9.8% vs 5.5%），过去两年Essex Property Trust的营收复合增速更高（6.0% vs 4.9%）
Balchem Corp是一家全球特种化学品与营养原料供应商，核心业务覆盖人类营养、动物保健、制药、工业应用四大领域，为北美、欧洲、亚太等地区的客户提供定制化专用原料产品。
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
BCPC vs ESS — 直观对比
营收规模更大
ESS
是对方的1.8倍
$263.6M
营收增速更快
BCPC
高出4.3%
5.5%
净利率更高
ESS
高出3.0%
14.9%
两年增速更快
ESS
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $263.6M | $479.6M |
| 净利润 | $39.2M | $85.7M |
| 毛利率 | 35.6% | 70.0% |
| 营业利润率 | 19.8% | 31.7% |
| 净利率 | 14.9% | 17.9% |
| 营收同比 | 9.8% | 5.5% |
| 净利润同比 | 16.8% | -71.6% |
| 每股收益（稀释后） | $1.21 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCPCESS
| Q4 25 | $263.6M | $479.6M | ||
| Q3 25 | $267.6M | $473.3M | ||
| Q2 25 | $255.5M | $469.8M | ||
| Q1 25 | $250.5M | $464.6M | ||
| Q4 24 | $240.0M | $454.5M | ||
| Q3 24 | $239.9M | $450.7M | ||
| Q2 24 | $234.1M | $442.4M | ||
| Q1 24 | $239.7M | $426.9M |
净利润BCPCESS
| Q4 25 | $39.2M | $85.7M | ||
| Q3 25 | $40.3M | $172.7M | ||
| Q2 25 | $38.3M | $231.5M | ||
| Q1 25 | $37.1M | $212.8M | ||
| Q4 24 | $33.6M | $301.7M | ||
| Q3 24 | $33.8M | $125.5M | ||
| Q2 24 | $32.1M | $99.0M | ||
| Q1 24 | $29.0M | $285.1M |
毛利率BCPCESS
| Q4 25 | 35.6% | 70.0% | ||
| Q3 25 | 35.7% | 69.2% | ||
| Q2 25 | 36.4% | 70.7% | ||
| Q1 25 | 35.2% | 69.6% | ||
| Q4 24 | 36.0% | 70.0% | ||
| Q3 24 | 35.6% | 69.5% | ||
| Q2 24 | 35.5% | 70.8% | ||
| Q1 24 | 34.0% | 69.7% |
营业利润率BCPCESS
| Q4 25 | 19.8% | 31.7% | ||
| Q3 25 | 20.4% | 44.5% | ||
| Q2 25 | 20.1% | 59.5% | ||
| Q1 25 | 20.4% | 55.3% | ||
| Q4 24 | 19.8% | 67.0% | ||
| Q3 24 | 20.0% | 28.6% | ||
| Q2 24 | 19.6% | 31.1% | ||
| Q1 24 | 17.4% | 31.0% |
净利率BCPCESS
| Q4 25 | 14.9% | 17.9% | ||
| Q3 25 | 15.1% | 36.5% | ||
| Q2 25 | 15.0% | 49.3% | ||
| Q1 25 | 14.8% | 45.8% | ||
| Q4 24 | 14.0% | 66.4% | ||
| Q3 24 | 14.1% | 27.8% | ||
| Q2 24 | 13.7% | 22.4% | ||
| Q1 24 | 12.1% | 66.8% |
每股收益（稀释后）BCPCESS
| Q4 25 | $1.21 | $1.24 | ||
| Q3 25 | $1.24 | $2.56 | ||
| Q2 25 | $1.17 | $3.44 | ||
| Q1 25 | $1.13 | $3.16 | ||
| Q4 24 | $1.03 | $4.00 | ||
| Q3 24 | $1.03 | $1.84 | ||
| Q2 24 | $0.98 | $1.45 | ||
| Q1 24 | $0.89 | $4.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $76.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $5.5B |
| 总资产 | $1.7B | $13.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCPCESS
| Q4 25 | $74.6M | $76.2M | ||
| Q3 25 | $65.1M | $66.0M | ||
| Q2 25 | $65.4M | $58.7M | ||
| Q1 25 | $49.9M | $98.7M | ||
| Q4 24 | $49.5M | $66.8M | ||
| Q3 24 | $73.7M | $71.3M | ||
| Q2 24 | $63.7M | $55.2M | ||
| Q1 24 | $60.3M | $499.0M |
总债务BCPCESS
| Q4 25 | — | — | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.2B | ||
| Q1 24 | — | $6.6B |
股东权益BCPCESS
| Q4 25 | $1.3B | $5.5B | ||
| Q3 25 | $1.3B | $5.6B | ||
| Q2 25 | $1.3B | $5.6B | ||
| Q1 25 | $1.2B | $5.6B | ||
| Q4 24 | $1.1B | $5.5B | ||
| Q3 24 | $1.2B | $5.4B | ||
| Q2 24 | $1.1B | $5.5B | ||
| Q1 24 | $1.1B | $5.5B |
总资产BCPCESS
| Q4 25 | $1.7B | $13.2B | ||
| Q3 25 | $1.7B | $13.2B | ||
| Q2 25 | $1.7B | $13.2B | ||
| Q1 25 | $1.6B | $13.2B | ||
| Q4 24 | $1.6B | $12.9B | ||
| Q3 24 | $1.6B | $12.6B | ||
| Q2 24 | $1.6B | $12.5B | ||
| Q1 24 | $1.6B | $12.9B |
负债/权益比BCPCESS
| Q4 25 | — | — | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.22× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | — | 1.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.3M | $1.1B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.72× | 12.53× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BCPCESS
| Q4 25 | $67.3M | $1.1B | ||
| Q3 25 | $65.6M | $342.6M | ||
| Q2 25 | $47.3M | $216.1M | ||
| Q1 25 | $36.5M | $281.5M | ||
| Q4 24 | $52.3M | $1.1B | ||
| Q3 24 | $51.3M | $316.2M | ||
| Q2 24 | $45.0M | $218.9M | ||
| Q1 24 | $33.4M | $314.9M |
现金转化率BCPCESS
| Q4 25 | 1.72× | 12.53× | ||
| Q3 25 | 1.63× | 1.98× | ||
| Q2 25 | 1.23× | 0.93× | ||
| Q1 25 | 0.98× | 1.32× | ||
| Q4 24 | 1.56× | 3.54× | ||
| Q3 24 | 1.52× | 2.52× | ||
| Q2 24 | 1.40× | 2.21× | ||
| Q1 24 | 1.15× | 1.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
ESS
暂无分部数据
